Company Description
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer.
The company’s proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer.
Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors.
The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells.
Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Country | United States |
Founded | 2015 |
IPO Date | Jul 20, 2018 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 331 |
CEO | Sushil Patel |
Contact Details
Address: 500 Unicorn Park Drive, Suite 303 Woburn, Massachusetts 01801 United States | |
Phone | 781 222 9600 |
Website | replimune.com |
Stock Details
Ticker Symbol | REPL |
Exchange | NASDAQ |
Fiscal Year | April - March |
Reporting Currency | USD |
CIK Code | 0001737953 |
CUSIP Number | 76029N106 |
ISIN Number | US76029N1063 |
Employer ID | 82-2082553 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Dr. Sushil Patel Ph.D. | Chief Executive Officer and Director |
Philip Astley-Sparke F.S.A. | Executive Chairman |
Emily Luisa Hill | Chief Financial Officer |
Dr. Konstantinos Xynos M.B.A., M.D., Ph.D. | Chief Medical Officer |
Dr. Robert Coffin Ph.D. | Founder, Chief Scientist and Director |
Andrew Schwendenman | Chief Accounting Officer and Treasurer |
Christopher Sarchi | Chief Commercial Officer |
Paul Bullock | Chief Manufacturing Officer and Framingham Site Head |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Nov 19, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Nov 12, 2024 | 10-Q | Quarterly Report |
Nov 12, 2024 | 8-K | Current Report |
Nov 4, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Oct 16, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |